Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects.

MLA

Liu, Li, et al. “Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects.” Clinical Pharmacology in Drug Development, vol. 9, no. 2, Feb. 2020, pp. 267–76. EBSCOhost, https://doi.org/10.1002/cpdd.717.

APA

Liu, L., Ding, Y., Jiao, Z., Wu, M., Li, C., Liu, J., Liu, C., Hu, Y., Li, Q., & Zhang, H. (2020). Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development, 9(2), 267–276. https://doi.org/10.1002/cpdd.717

Chicago

Liu, Li, Yanhua Ding, Zheng Jiao, Min Wu, Cuiyun Li, Jingrui Liu, Chengjiao Liu, Yue Hu, Qingmei Li, and Hong Zhang. 2020. “Clinical Evaluation of the Tolerability, Pharmacokinetics, and Inhibition of Platelet Aggregation of Eptifibatide in Healthy Chinese Subjects.” Clinical Pharmacology in Drug Development 9 (2): 267–76. doi:10.1002/cpdd.717.